HF Advisory Group LLC Acquires New Holdings in Stryker Corporation $SYK

HF Advisory Group LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,717 shares of the medical technology company’s stock, valued at approximately $541,000.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. VanderPol Investments L.L.C. grew its position in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC raised its position in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC raised its position in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, Guyasuta Investment Advisors Inc. grew its position in Stryker by 1.7% during the fourth quarter. Guyasuta Investment Advisors Inc. now owns 1,747 shares of the medical technology company’s stock worth $614,000 after buying an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 0.1%

Shares of SYK stock opened at $338.85 on Monday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $320.11 and a two-hundred day moving average price of $333.92. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a market cap of $129.97 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on SYK shares. Canaccord Genuity Group decreased their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Royal Bank Of Canada cut their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Raymond James Financial set a $370.00 target price on shares of Stryker in a research note on Friday, July 31st. Finally, Citizens Jmp dropped their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.